对话杭州脉流科技有限公司 

对话内容 

大家好！我是杭州脉流科技有限公司的向建平。非常荣幸能够借助全球数字贸易博览会这一国际化平台，与大家分享脉流科技在AI浪潮中的探索成果与实践收获。

Hello everyone! I am Jianping Xiang from ArteryFlow Technology from Hangzhou. It is a great honor to share our innovation in the AI era through the Global Digital Trade Expo.

脉流科技专注于心脑血管疾病领域，我们将空气动力学和火箭科学应用在生命科学，通过血流动力学和AI进行疾病的筛查、诊断以及治疗方案。我们始终坚信，技术创新是驱动医疗进步的核心引擎。

ArteryFlow focuses on AI application in cardiovascular diseases. We apply hardcore technology －aerodynamics and rocket science into life science via hemodynamics and AI for disease screening, diagnosis, and treatment planning.We firmly believe that technological innovation is the core engine driving medical progress.

在核心产品方面，我们的无创冠脉血流评估产品AccuFFRangio 是全球唯一同时获得中国NMPA、美国FDA和欧洲CE三重认证的产品。这一认证成果，标志着我们的创新产品已具备服务全球患者的能力，正从本土走向世界。

Regarding our core products, our AccuFFRangio for noninvasively assessing heart ischemia is the only product worldwide that has simultaneously obtained the triple approval from China NMPA, the US FDA, and the European CE. This achievement shows that our innovative products are now equipped to serve patients globally and are moving from local to world markets.

更令我们振奋的是，2026年7月，脉流科技有幸在日内瓦荣获联合国世界知识产权组织（WIPO）全球奖。这份殊荣，不仅是对我们自主知识产权体系的高度认可，更是国际社会对中国医疗科技创新能力的积极肯定。

What excites us even more is that in July 2026, ArteryFlow was honored to receive the WIPO Global Award from the United Nations in Geneva. This accolade is not only a high recognition of our independent IP system but also a positive affirmation of China’s medical technology innovation globally.

之所以能接连通过全球最严苛的监管认证、并赢得WIPO的高度肯定，底层逻辑正源于我们扎实的技术创新。截至2026年6月，脉流科技在全球已获得131项授权发明专利，累计发表学术论文356篇，这些数字正是我们持续深耕的最好注脚。

The reason why we have been able to successively pass the world’s most stringent regulatory approval and earn high recognition from WIPO lies in the underlying logic of our solid technology innovation. As of June 2026, ArteryFlow has obtained 131 authorized patents globally, and published a total of 356 academic papers. These figures are the best testament to our continued dedication.

数字贸易的蓬勃发展，为国产医疗创新“出海”打开了广阔空间。在上一届数贸会上，我们集中展示了面向心脑血管疾病的智能诊疗产品，并与众多企业、科研机构深入交流，收获了宝贵的合作机会与行业洞察。

The vigorous development of digital trade has opened up broad opportunities for domestic medical innovations to go global. At the previous Digital Trade Expo, we showcased our AI products for cardiovascular diseases, and engaged in in-depth exchanges with numerous enterprises and research institutions, gaining valuable cooperation opportunities and industry insights.

面向未来，我们将紧抓数字贸易带来的机遇与挑战，将本土创新转化为国际竞争力，让智慧医疗成果惠及更多国家和地区的医患群体。

Looking to the future, we will seize the opportunities and meet the challenges brought by digital trade, transform local innovation into international competitiveness, and enable smart healthcare achievements to benefit more patients and healthcare providers in more countries and regions.

本次数贸会，我们将展示针对冠脉、颅内动脉等不同场景的智能化解决方案，诚挚邀请您莅临位于7B号馆的第四届专利密集型产品展览专区（展位号Z001）和2号馆的“AI未来”主题展区（展位号2-T001），共探数字贸易下医疗产业出海新路径。

At this Digital Trade Expo, we will showcase intelligent solutions for different scenarios such as coronary and cerebral arteries. We sincerely invite you to visit our place in either the Preface Hall or Hall 7B, where we can jointly explore new paths for the medical industry to go global.

数字贸易，商通全球。第五届全球数字贸易博览会，我们杭州见！

Digital Trade, Global Access. See you at the 5th Global Digital Trade Expo in Hangzhou!

Thank you!

企业简介 

脉流科技成立于2017年6月，是一家专注为全球提供领先的心脑血管疾病精准智能诊疗及解决方案的国家高新技术企业、重点专精特新企业。公司斩获2026年联合国世界知识产权组织（WIPO）全球奖，牵头以及参与多项国家级、省级重点科研计划，包括“十三五”国家重点研发计划、国家科技创新2030-“癌症、心脑血管、呼吸和代谢性疾病防治研究”重大项目、以及“尖兵”“领雁”科技计划项目等，并先后荣获省科技进步奖一等奖、省研发中心、工程研究中心以及“浙江省科技新小龙”称号，被纳入规上工业企业库和上市后备企业库，公司已取得国内外发明专利124项，已发表SCI论文356篇，彰显了公司在心脑血管智能诊疗领域的科研引领地位。

在3位“国家级领军人才”带领下，团队以技术创新为驱动，自主研发的多款创新产品（AccuFFR系列、AccuICAS、AneuFlow和AneuGuide）等填补了国内外心脑血管智能诊疗领域的空白，在中国、美国和欧洲已累计获得21个注册证，其中“冠脉血管狭窄精准功能学评估技术”和“脑血管功能学评估技术”是全球唯一同时获得中国NMPA、美国FDA与欧盟CE认证的产品。面向未来，脉流科技从精准诊疗迈向全生命周期管理，持续输出技术成果并产业化应用，为全球医疗与人类健康贡献中国智慧。